Loading stock data…
CRL
$188.50-1.35 (-0.71%)
Market OpenUpdated 1:30 PM EDT
Charles River Laboratories International, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Charles River Laboratories International, Inc. in the Healthcare sector is trading at $188.50. Wall Street consensus targets $212.27 (15 analysts), implying a +12.6% move over the next 12 months. The stock is currently 18% below its 52-week high of $228.88, remaining 6.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +12.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $995.83M↑ | $994.23M↓ | $1.00B↓ | $1.03B↑ | $984.17M |
| Gross Profit | $294.66M↓ | $309.68M↓ | $338.79M↓ | $357.07M↑ | $317.73M |
| Operating Income | $119.90M↑ | $92.53M↓ | $133.80M↑ | $100.13M↑ | $74.67M |
| Net Income | -$14.84M↑ | -$276.56M↓ | $54.42M↑ | $52.33M↑ | $25.47M |
Peer Comparison
JNJUNHPFE
Fundamentals
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.28%
Volume
Today's trading volume
291,881
Recent News
Reasons Why You Should Hold Charles River Stock in Your Portfolio
CRAI benefits from rising demand for specialized advisory services, but AI, talent costs and fierce competition pose risks.
Assessing Charles River Laboratories (CRL) Valuation After Mixed Returns And Contrasting Undervaluation Signals
Stock performance snapshot and recent trading context Charles River Laboratories International (CRL) has recently drawn investor attention after a period of mixed returns, including a gain of 2.9% over the past day and 9.4% over the past week. See our latest analysis for Charles River Laboratories International. That short burst of buying interest sits against a softer recent pattern, with the 1 month share price return of 4.38% and the year to date share price return down 11.14%, even though...
The Zacks Analyst Blog Highlights Stantec, CBIZ and Charles River
Stantec, CBIZ and Charles River Associates stand out as consulting services picks despite industry underperformance and weak near-term rankings.
Zacks Industry Outlook Highlights Stantec, CBIZ and Charles River
Stantec, CBIZ and Charles River have been highlighted in this Industry Outlook article.
Here Are Friday’s Top Wall Street Analyst Research Calls: Best Buy, Cogent Communications, Dell Technologies, EPAM Systems, Federal Realty, Gap, Snowflake, Viper Energy, and More
Pre-Market Stock Futures: Futures are trading higher after yet another winning day for Wall Street, as all major indices finished the day higher after starting the session lower. Once again, all four indices we track for readers posted all-time highs as the AI/Data Center, Memory Chip rally continues to roll on. Healthcare and consumer stocks ... Here Are Friday’s Top Wall Street Analyst Research Calls: Best Buy, Cogent Communications, Dell Technologies, EPAM Systems, Federal Realty, Gap, Snowfl